exam1A.fall09final

exam1A.fall09final - PubH 6450 Exam 1 (10/08/09) NAME:_...

Info iconThis preview shows pages 1–3. Sign up to view the full content.

View Full Document Right Arrow Icon
A 1 PubH 6450 NAME:_____________________________________________ Exam 1 (10/08/09) Lecture Instructor (please circle): Susan Telke Lynn Eberly Directions: This is an open-book, open-notes exam; however, sharing of books, notes, handouts, homework or lab papers, calculators, or verbal comments is not permitted. You may use a calculator of your choosing, but laptop computers and any kind of internet connection are not permitted. For multiple choice questions, please clearly indicate your answer(s). For short answer problems, please show all relevant work necessary to arrive at a solution, as partial credit will be awarded. DO NOT LOOK AT OR BEGIN THE EXAM UNTIL THE INSTRUCTOR ANNOUNCES THAT THE EXAM IS STARTING. You will have from 1:25pm to 3:20pm to complete this exam, so do not spend too much time on any one problem. With such a big class, there is always someone who needs to take the exam early or late. After the exam is over, DO NOT DISCUSS THIS EXAM with anyone who was not in this same room taking it with you. We anticipate returning the exams in class on Tuesday. Good luck!!
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
A 2 Problem 1: Modeling the complexity of sickle cell disease pathophysiology is difficult. Creating a disease severity score that models the risk of death would be clinically useful. Using data from 3380 patients followed in the Cooperative Study of Sickle Cell Disease (CSSCD), Sebastiani, et al. created a severity score ranging from 0 (least severe) to 1 (most severe). Recruitment for CSSCD started in 1978 and continued for some patients into 1988. All participants were followed on average for 5 years. Several variables were recorded, including: participant age in years, race category, severity score, and total bilirubin level in mg/dL at enrollment, and adverse events (e.g., pain) and outcomes (death or survival) over study follow- up. Age was later grouped into three age categories (2-18 years, 19-40 years and greater than 40 years). [Source: Sebastiani, et al. Blood 2007; 110: 2727-2735] Use this information to answer questions A thru G. A.
Background image of page 2
Image of page 3
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 11/21/2011 for the course PUBH 6450 taught by Professor Andymugglin during the Fall '10 term at Minnesota.

Page1 / 9

exam1A.fall09final - PubH 6450 Exam 1 (10/08/09) NAME:_...

This preview shows document pages 1 - 3. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online